Patents by Inventor Roberto Burioni

Roberto Burioni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7727529
    Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: June 1, 2010
    Assignee: General Antibodies and Biotechnologies S.R.L
    Inventor: Roberto Burioni
  • Publication number: 20100074906
    Abstract: The present invention provides novel antibody sequences that bind Varicella Zoster Virus (VZV) and neutralize VZV infection. The novel sequences can be used for the medical management of VZV infection, in particular for detecting the virus or for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of VZV infection.
    Type: Application
    Filed: February 6, 2008
    Publication date: March 25, 2010
    Applicant: RIBOVAX BIOTECHNOLOGIES SA
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20100008905
    Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.
    Type: Application
    Filed: January 29, 2008
    Publication date: January 14, 2010
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20090203548
    Abstract: A complex able to detect an analyte (CRA) comprising a particle expressing on its outer surface a compound having specific binding capability (CDCLS) for the analyte and stably including at least one nucleic acid reporter sequence being univocally associated to the CDCLS; process for its construction and uses thereof.
    Type: Application
    Filed: August 9, 2005
    Publication date: August 13, 2009
    Inventor: Roberto Burioni
  • Publication number: 20080312101
    Abstract: The present invention provides novel technologies for producing and screening fusion proteins on the surface of filamentous phage. In particular, a single vector can be used for generating cell and phage libraries containing a given series of protein sequences fused to either one or other of two phage coat proteins. This approach simplifies and improves the efficiency of the subsequent phage display-based selection of protein-binding molecules having therapeutic or diagnostic utility, such as antibodies, peptides, or epitope-binding regions.
    Type: Application
    Filed: July 6, 2006
    Publication date: December 18, 2008
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20080241162
    Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines.
    Type: Application
    Filed: May 28, 2008
    Publication date: October 2, 2008
    Inventor: ROBERTO BURIONI
  • Patent number: 7314919
    Abstract: An human antibody anti-NS3 protein of the hepatitis C virus (HCV) is described, as will as synthetic and recombinant fragments thereof able to inhibit the helicase activity of the NS3 protein, both in vitro and in vivo, and uses thereof.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: January 1, 2008
    Assignee: Biostrands S.r.l.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 7060799
    Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: June 13, 2006
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
  • Publication number: 20050130320
    Abstract: The invention describes a method for identifying the level of various proteins in a cells or tissue and also comparing the levels of the same protein in two different tissues which we have termed as Antibody Microarray Proteomics Technology (AMP Technology). Proteins that are differentially expressed between a normal and disease tissue could be involved in the disease process and disease tissue could be involved in the disease process and hereby makes it a potential drug or diagnostic target. AMP technology makes use of the method of phage display selection or similar combinatorial antibody selection techniques to select antibodies to a given protein. Antibodies to all of most proteins present in the diseased and normal tissue are produced in an appropriate animal (mice) and mRNA encoding antibodies are isolated, cloned into filamentous phage (or bacteria or yeast) vectors such that the antibodies are expressed as a fusion with the phage filaments.
    Type: Application
    Filed: November 8, 2001
    Publication date: June 16, 2005
    Inventors: Shaji. George, Roberto Burioni
  • Publication number: 20050084845
    Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines.
    Type: Application
    Filed: January 29, 2003
    Publication date: April 21, 2005
    Inventor: Roberto Burioni
  • Publication number: 20040214994
    Abstract: An human antibody anti-NS3 protein of the hepatitis C virus (HCV) is described, as will as synthetic and recombinant fragments thereof able to inhibit the helicase activity of the NS3 protein, both in vitro and in vivo, and uses thereof.
    Type: Application
    Filed: February 23, 2004
    Publication date: October 28, 2004
    Inventors: Roberto Burioni, Massimo Clementi
  • Publication number: 20020168629
    Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.
    Type: Application
    Filed: February 19, 2002
    Publication date: November 14, 2002
    Applicant: The Scripps Research Institute, a California Corporation
    Inventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
  • Patent number: 6376170
    Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: April 23, 2002
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
  • Patent number: 6156313
    Abstract: The present invention describes human monoclonal antibodies which immunoreact with Herpes simplex virus Type-1 and Type-2. Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as nucleic acids and cell lines for producing the monoclonal antibodies.
    Type: Grant
    Filed: May 6, 1997
    Date of Patent: December 5, 2000
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Robert A. Williamson, Roberto Burioni, Pietro Paolo Sanna